<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25189222</article-id><article-id pub-id-type="pmc">4180966</article-id><article-id pub-id-type="publisher-id">471</article-id><article-id pub-id-type="doi">10.1186/s13054-014-0471-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Long</surname><given-names>Wei</given-names></name><address><email>longwei2290@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Li-juan</given-names></name><address><email>lily_juan@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Huang</surname><given-names>Gao-zhong</given-names></name><address><email>huanggaozhong@medmail.com.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xue-min</given-names></name><address><email>xuemin_zhangz@163.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yi-cui</given-names></name><address><email>yicuizhang_z@163.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Jian-guo</given-names></name><address><email>jianguotang5hospital@gmail.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yu</given-names></name><address><email>yuzhang_zzz@163.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Gang</given-names></name><address><email>happy_ggang@sina.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Department of Internal and Geriatric Medicine, Shanghai Jiao Tong University Affiliated Sixth People&#x02019;s Hospital, 222 Huan Hu Xi San Road, Shanghai, 201306 China </aff><aff id="Aff2"><label/>Department of Trauma-Emergency-Critical Care Medicine, Fudan University Affiliated Shanghai Fifth People&#x02019;s Hospital, 128 Rui Li Road, Shanghai, 200240 China </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>18</volume><issue>5</issue><elocation-id>471</elocation-id><history><date date-type="received"><day>12</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Long et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>Patients with severe acute exacerbations of asthma often receive inappropriate antibiotic treatment. We aimed to determine whether serum procalcitonin (PCT) levels can effectively and safely reduce antibiotic exposure in patients experiencing exacerbations of asthma.</p></sec><sec><title>Methods</title><p>In this randomized controlled trial, a total of 216 patients requiring hospitalization for severe acute exacerbations of asthma were screened for eligibility to participate and 169 completed the 12-month follow-up visit. Patients were randomized to either PCT-guided (PCT group) or standard (control group) antimicrobial therapy. In the control group, patients received antibiotics according to the attending physician&#x02019;s discretion; in the PCT group, patients received antibiotics according to an algorithm based on serum PCT levels. The primary end point was antibiotic exposure; secondary end points were clinical recovery, length of hospital stay, clinical and laboratory parameters, spirometry, number of asthma exacerbations, emergency room visits, hospitalizations and need for corticosteroid use due to asthma.</p></sec><sec><title>Results</title><p>PCT guidance reduced antibiotic prescription (48.9% versus 87.8%, respectively; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and antibiotic exposure (relative risk, 0.56; 95% confidence interval, 0.44 to 0.70; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) compared to standard therapy. There were no significant differences in clinical recovery, length of hospital stay or clinical, laboratory and spirometry outcomes in both groups. Number of asthma exacerbations, emergency room visits, hospitalizations and need for corticosteroid use due to asthma were similar during the 12-month follow-up period.</p></sec><sec><title>Conclusion</title><p>A PCT-guided strategy allows antibiotic exposure to be reduced in patients with severe acute exacerbation of asthma without apparent harm.</p></sec><sec><title>Trial registration</title><p>Chinese Clinical Trial Register <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org/en/proj/show.aspx?proj=3517">ChiCTR-TRC-12002534</ext-link> (registered 26 September 2012)</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Asthma is a problem worldwide, with an estimated incidence of 300 million affected individuals and 250,000 annual deaths from asthma [<xref ref-type="bibr" rid="CR1">1</xref>]. Acute exacerbations of asthma account for nearly 2 million emergency department (ED) visits and 500,000 admissions each year in the United States, frequently ranking as a major cause of absence from work and decreased productivity and incurring the greatest health-care costs [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>]. Severe exacerbations of asthma are potentially life-threatening and often put patients at increased risk of ED admission and hospitalization.</p><p>Because most exacerbations of asthma are associated with viral respiratory tract infection (RTI) and bacterial infection seems to play only a minor role, global asthma management guidelines do not recommend routine use of antibiotics [<xref ref-type="bibr" rid="CR4">4</xref>]. However, in countries with high prescription rates for antibiotics, many asthma patients with exacerbations are treated with antibiotics, leading to antibiotic overuse and bacterial resistance [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. In the United States, approximately 22% of acute asthma patients in the ED receive an antibiotic unnecessarily [<xref ref-type="bibr" rid="CR7">7</xref>]. In England, a high antibiotic prescription rate (57%) was observed in asthma patients [<xref ref-type="bibr" rid="CR6">6</xref>]. In our previous study in China, about 70% of patients with mild to moderate acute exacerbation of asthma received antibiotics [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>As many as 75% of all antibiotic doses are prescribed for RTIs, such as acute bronchitis, community-acquired pneumonia (CAP), acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD), despite their mainly viral cause [<xref ref-type="bibr" rid="CR8">8</xref>]. This inappropriate use of antibiotics is believed to be a main cause of the spread of bacterial resistance [<xref ref-type="bibr" rid="CR9">9</xref>]. There is a need to reduce unnecessary antibiotic use during treatment of RTI, and much effort has been put into the search for sensitive and specific tools to guide antibiotic therapy in RTI patients. Clinical trials that have used procalcitonin (PCT) to guide antibiotic therapy for patients with RTI have shown that a biomarker-driven algorithm can cut antibiotic prescribing significantly and that this can be achieved without any increase in adverse events or treatment failures [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. PCT-guided antibiotic stewardship reduced initial antibiotic prescription rates by 40% to 50% in patients with LRTI (lower respiratory tract infection) presenting to the ED [<xref ref-type="bibr" rid="CR13">13</xref>] and by 70% to 80% in ambulatory patients presenting to their general physicians [<xref ref-type="bibr" rid="CR15">15</xref>] and reduced total antibiotic exposure in CAP by 40% to 50% [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>In our previous study, we demonstrated that PCT can be used accurately and effectively to determine whether acute asthma patients have bacterial infections and to guide the use of antibiotics in the treatment of acute exacerbation of mild to moderate asthma [<xref ref-type="bibr" rid="CR5">5</xref>]. However, we included few severe asthma patients in the study, and the study had only a 6-week follow-up period. We therefore undertook a randomized controlled study to assess the usefulness of PCT guidance for antibiotic use in hospitalized patients with severe acute exacerbation of asthma, and this time included a 12-month follow-up period.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Patients and study design</title><p>This was a randomized controlled trial. The study was approved by the Shanghai Fifth People&#x02019;s Hospital Research Ethics Committee, and all patients or their legally authorized representatives provided written informed consent.</p><p>From January 2009 to December 2011, consecutive patients ages 18 to 65&#x000a0;years who were hospitalized in the Fifth People&#x02019;s Hospital of Shanghai with severe acute exacerbations of asthma were eligible for enrollment in the study. Asthma was defined according to the guidelines of the Global Initiative for Asthma [<xref ref-type="bibr" rid="CR4">4</xref>]. A severe asthma exacerbation was defined as at least one of the following [<xref ref-type="bibr" rid="CR18">18</xref>]: (1) need for systemic corticosteroids, or an increase from a stable maintenance dose, for at least 3&#x000a0;days and/or (2) hospitalization or ED visit because of asthma requiring systemic corticosteroids. Excluded were patients with antibiotic use within the previous 14&#x000a0;days, psychiatric disorders or other inability to give written informed consent, not being available for follow-up, severe immunosuppression, heart failure, cystic fibrosis, active tuberculosis, pregnancy and chest radiography&#x02013;confirmed pneumonia.</p><p>Baseline assessment included asthma and medical history, vital signs, physical examination, routine blood tests, chest radiography, spirometry and clinical events related to asthma within the previous year, including asthma exacerbations, need for systemic corticosteroids, ED visits and hospitalizations for asthma. Spontaneously expectorated sputum samples were obtained to identify potential pathogenic microorganisms.</p><p>Serum PCT was measured using the B.R.A.H.M.S. PCT sensitive Kryptor (B.R.A.H.M.S., Hennigsdorf, Germany), a rapid sensitive assay with a functional sensitivity of 0.06&#x000a0;&#x003bc;g/L and a lower detection limit of 0.02&#x000a0;&#x003bc;g/L with an assay time of less than 30&#x000a0;minutes.</p></sec><sec id="Sec4"><title>Study intervention</title><p>Eligible patients were randomized to either PCT-guided (PCT group) or standard antimicrobial therapy (control group). Allocation to either intervention was conducted according to computer-generated random numbers produced by an independent statistician. After randomization, an opaque, sealed, sequentially numbered envelope containing the PCT or control protocol was prepared for each subject according to group assignment. The control group received antibiotic according to the discretion of the treating physician, who was unaware of the patient&#x02019;s PCT levels. PCT levels of patients in the PCT group were provided to their attending physicians. Patients in the PCT group were treated with antibiotics on the basis of a PCT algorithm validated in previous studies [<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]: antibiotic treatment was strongly discouraged when serum PCT level was less than 0.1&#x000a0;&#x003bc;g/L; antibiotic treatment was discouraged when serum PCT level was less than 0.25&#x000a0;&#x003bc;g/L; and antibiotic treatment was encouraged when serum PCT level was higher than 0.25&#x000a0;&#x003bc;g/L. When antibiotics were withheld from patients, a second measurement of the PCT level was mandatory within 6 to 24&#x000a0;hours for safety reasons. The use of antibiotics was recommended if this second measurement was higher than 0.25&#x000a0;&#x003bc;g/L. The physicians were permitted to overrule the algorithm, but they had to indicate the reasons for overruling. The patients were reevaluated 12&#x000a0;months after discharge.</p></sec><sec id="Sec5"><title>Outcome measures</title><p>The primary end point was antibiotic use, expressed as rate of antibiotic prescriptions in percentage and relative risk of antibiotic exposure. Secondary end points included measures of treatment success; length of hospital stay; clinical, laboratory and spirometry outcomes at discharge; and results of spirometry at the 12-month follow-up examination, as well as the results of the Asthma Control Test (ACT) [<xref ref-type="bibr" rid="CR19">19</xref>], the results of the Asthma Quality of Life Questionnaire (AQLQ) [<xref ref-type="bibr" rid="CR20">20</xref>] at the 12-month follow-up visit and the clinical events during the 12-month follow-up period, including numbers of asthma exacerbations, ED visits, hospitalizations and need for systemic corticosteroid use for treatment of asthma.</p><p>The ACT was used to determine the level of disease control. The overall ACT score varies from 5 (very poor asthma control) to 25 (full asthma control), with scores ranging from 20 to 24 defining controlled asthma, scores ranging from 16 to 19 partly indicating controlled asthma and scores &#x02264;15 identifying uncontrolled asthma. The AQLQ was used to evaluate quality of life. The AQLQ consists of 32 items covering asthma-related symptoms and limitations during the 2&#x000a0;weeks preceding administration of the questionnaire, and responses are scored on a scale of 1 to 7, with higher numbers indicating a better quality of life. The validity and reliability of the ACT and the AQLQ have been evaluated for use in Chinese patients with asthma [<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec6"><title>Statistical analysis</title><p>Discrete variables are expressed as percentages and continuous variables as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) for variables normally distributed and as median with interquartile range (IQR) for nonnormally distributed data. Comparability of groups was analyzed by &#x003c7;<sup>2</sup> test, two-sampled <italic>t</italic>-test and/or Mann-Whitney <italic>U</italic> test as appropriate. Relative risk (RR) was calculated with 95% confidence interval (CI). <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was defined as statistically significant.</p><p>Assuming 90% of the patients in the control group would use antibiotics and anticipating a 15% decrease in antibiotic usage in the PCT group, a sample size of 158 patients (79 patients per group) was necessary to detect a significant difference in antibiotic prescription rate between the groups with 80% power and an &#x003b1; error of 0.05. To account for possible loss of patients to follow-up, we planned to enroll 180 patients.</p><p>The time to the first occurrence of asthma-related clinical events (exacerbation and hospitalization) was analyzed using Kaplan-Meier survival curves and by the logrank test. For outcomes during the follow-up period, we performed per-protocol analyses. Data were analyzed using SPSS version 16 for Windows statistical software (SPSS, Chicago, IL, USA).</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Study population</title><p>A total of 216 patients with severe acute exacerbations of asthma were screened for eligibility to participate in this study. Among this original sample, 180 were eligible and randomized into the PCT group (<italic>n</italic>&#x02009;=&#x02009;90) or the control group (<italic>n</italic>&#x02009;=&#x02009;90); of these 180 patients, 169 completed the 12-month follow-up visit, and 5 patients in the PCT group and 6 patients in the control group were lost to follow-up (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The two treatment groups were matched at baseline for demographic, clinical and laboratory features (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Study flow diagram displaying the number of screened, excluded, randomized and analyzed patients.</bold> PCT, Procalcitonin.</p></caption><graphic xlink:href="13054_2014_471_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Characteristics of the study population at baseline</bold>
<sup><bold>a</bold></sup>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Characteristics</bold>
</th><th>
<bold>PCT group (</bold>
<bold><italic>n</italic></bold>&#x02009;
<bold>=&#x02009;90)</bold>
</th><th>
<bold>Control group (</bold>
<bold><italic>n</italic></bold>&#x02009;
<bold>=&#x02009;90)</bold>
</th><th>
<bold><italic>P-</italic></bold>
<bold>value</bold>
</th></tr></thead><tbody><tr valign="top"><td>Age in years, mean (SD)</td><td>40.4&#x02009;&#x000b1;&#x02009;12.3</td><td>39.4&#x02009;&#x000b1;&#x02009;11.7</td><td>0.594</td></tr><tr valign="top"><td>Male sex, <italic>n</italic> (%)</td><td>49 (54.4)</td><td>52 (57.8)</td><td>0.652</td></tr><tr valign="top"><td>Duration of asthma in years, mean (SD)</td><td>22.6&#x02009;&#x000b1;&#x02009;11.7</td><td>21.8&#x02009;&#x000b1;&#x02009;12.1</td><td>0.621</td></tr><tr valign="top"><td>Smoking status, <italic>n</italic> (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Current</td><td>17 (18.9)</td><td>14 (15.6)</td><td>0.553</td></tr><tr valign="top"><td>&#x02003;Former</td><td>29 (32.2)</td><td>28 (31.1)</td><td>0.872</td></tr><tr valign="top"><td>&#x02003;Never</td><td>44 (48.9)</td><td>48 (53.3)</td><td>0.551</td></tr><tr valign="top"><td>Fever, <italic>n</italic> (%)</td><td>22 (24.4)</td><td>17 (18.9)</td><td>0.365</td></tr><tr valign="top"><td>Cough, <italic>n</italic> (%)</td><td>69 (76.7)</td><td>63 (70.0)</td><td>0.312</td></tr><tr valign="top"><td>Sputum, <italic>n</italic> (%)</td><td>56 (62.2)</td><td>51 (56.7)</td><td>0.447</td></tr><tr valign="top"><td>Respiratory medication, <italic>n</italic> (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;ICS</td><td>23 (25.5)</td><td>27 (30.0)</td><td>0.505</td></tr><tr valign="top"><td>&#x02003;ICS&#x02009;+&#x02009;LABA</td><td>59 (65.5)</td><td>56 (62.2)</td><td>0.641</td></tr><tr valign="top"><td>HR, beats/min</td><td>101&#x02009;&#x000b1;&#x02009;18</td><td>104&#x02009;&#x000b1;&#x02009;16</td><td>0.319</td></tr><tr valign="top"><td>RR, breaths/min</td><td>25&#x02009;&#x000b1;&#x02009;7</td><td>24&#x02009;&#x000b1;&#x02009;6</td><td>0.471</td></tr><tr valign="top"><td>Systolic blood pressure, mmHg</td><td>111&#x02009;&#x000b1;&#x02009;20</td><td>108&#x02009;&#x000b1;&#x02009;19</td><td>0.271</td></tr><tr valign="top"><td>pH</td><td>7.35&#x02009;&#x000b1;&#x02009;0.08</td><td>7.36&#x02009;&#x000b1;&#x02009;0.07</td><td>0.984</td></tr><tr valign="top"><td>SaO<sub>2</sub>,%<sup>b</sup>
</td><td>89&#x02009;&#x000b1;&#x02009;5</td><td>88&#x02009;&#x000b1;&#x02009;4</td><td>0.304</td></tr><tr valign="top"><td>PaO<sub>2</sub>, mmHg<sup>b</sup>
</td><td>61&#x02009;&#x000b1;&#x02009;9</td><td>59&#x02009;&#x000b1;&#x02009;8</td><td>0.178</td></tr><tr valign="top"><td>PaCO<sub>2</sub>, mmHg<sup>b</sup>
</td><td>58&#x02009;&#x000b1;&#x02009;16</td><td>56&#x02009;&#x000b1;&#x02009;14</td><td>0.410</td></tr><tr valign="top"><td>CRP, mg/L</td><td>21.1&#x02009;&#x000b1;&#x02009;9.1</td><td>22.3&#x02009;&#x000b1;&#x02009;9.3</td><td>0.388</td></tr><tr valign="top"><td>WBC, &#x000d7;10<sup>9</sup>/L</td><td>11.8&#x02009;&#x000b1;&#x02009;4.1</td><td>11.4&#x02009;&#x000b1;&#x02009;3.7</td><td>0.598</td></tr><tr valign="top"><td>PCT, &#x003bc;g/L</td><td>0.107 (0.052 to 0.273)</td><td>0.114 (0.055 to 0.266)</td><td>0.912</td></tr><tr valign="top"><td>FEV<sub>1</sub>,% of predicted value</td><td>39.2&#x02009;&#x000b1;&#x02009;9.6</td><td>39.8&#x02009;&#x000b1;&#x02009;10.3</td><td>0.705</td></tr><tr valign="top"><td>Clinical events related to asthma in previous year, <italic>n</italic> (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Asthma exacerbations</td><td>78 (86.7)</td><td>75 (83.3)</td><td>0.531</td></tr><tr valign="top"><td>&#x02003;Emergency room visits</td><td>69 (76.7)</td><td>65 (72.2)</td><td>0.494</td></tr><tr valign="top"><td>&#x02003;Hospitalizations</td><td>17 (18.9)</td><td>14 (15.5)</td><td>0.553</td></tr><tr valign="top"><td>&#x02003;Need for systemic corticosteroids for &#x02265;3&#x000a0;days</td><td>53 (58.9)</td><td>49 (54.4)</td><td>0.547</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>CRP, C-reactive protein; FEV<sub>1</sub>, Forced expiratory volume in 1&#x000a0;second; HR, Heart rate; ICS, Inhaled corticosteroid; LABA, Long-acting &#x003b2;<sub>2</sub>-agonists; PaCO<sub>2</sub>, Partial pressure of carbon dioxide; PaO<sub>2</sub>, Partial pressure of oxygen; PCT, Procalcitonin; RR, Respiratory rate; SaO<sub>2</sub>, Arterial oxygen saturation; WBC, White blood cells. <sup>b</sup>Measured while patient was receiving oxygen therapy. Data are presented as number (%), median (IQR) or mean&#x02009;&#x000b1;&#x02009;SD.</p></table-wrap-foot></table-wrap></p><p>All patients received any one or a combination of the following medications for treatment of the exacerbation: theophylline, corticosteroids, &#x003b2;<sub>2</sub>-agonists and anticholinergic agents. There was a similar distribution of antibiotic use in both groups: macrolides (56.6%; PCT group, 32 cases; control group, 49 cases; <italic>P</italic>&#x02009;=&#x02009;0.489), fluoroquinolones (23.1%; PCT group, 12 cases; control group, 21 cases; <italic>P</italic>&#x02009;=&#x02009;0.924), aminopenicillin (11.2%; PCT group, 5 cases; control group, 11 cases; <italic>P</italic>&#x02009;=&#x02009;0.609), cephalosporins (9.1%; PCT group, 4 cases; control group, 9 cases; <italic>P</italic>&#x02009;=&#x02009;0.848). A single antibiotic was used in 108 patients (PCT group, 38 cases; control group, 70 cases; <italic>P</italic>&#x02009;=&#x02009;0.715), and combination therapy with two or more antibiotics was administered in 15 patients (PCT group, 6 cases; control group, 9 cases; <italic>P</italic>&#x02009;=&#x02009;0.715).</p><p>Sputum samples were obtained from 81 patients (PCT group, 39 cases; control group, 42 cases), and 24 causative microorganisms were isolated (PCT group, 11 organisms; control group, 13 organisms). The most frequently detected pathogens were <italic>Chlamydophila pneumoniae</italic> (PCT group, 4 organisms; control group, 6 organisms), followed by <italic>rhinovirus</italic> (PCT group, 1 organism; control group, 3 organisms) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Microbiology results from sputum in two groups</bold>
<sup><bold>a</bold></sup>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>Procalcitonin group (</bold>
<bold><italic>n</italic></bold>&#x02009;
<bold>=&#x02009;90)</bold>
</th><th>
<bold>Control group (</bold>
<bold><italic>n</italic></bold>&#x02009;
<bold>=&#x02009;90)</bold>
</th></tr></thead><tbody><tr valign="top"><td>
<italic>Influenza virus</italic>, <italic>n</italic>
</td><td>2</td><td>0</td></tr><tr valign="top"><td>
<italic>Rhinovirus</italic>, <italic>n</italic>
</td><td>1</td><td>3</td></tr><tr valign="top"><td>
<italic>Coronavirus</italic>, <italic>n</italic>
</td><td>1</td><td>1</td></tr><tr valign="top"><td>
<italic>Chlamydophila pneumoniae</italic>, <italic>n</italic>
</td><td>4</td><td>6</td></tr><tr valign="top"><td>
<italic>Mycoplasma pneumoniae</italic>, <italic>n</italic>
</td><td>1</td><td>0</td></tr><tr valign="top"><td>
<italic>Pseudomonas aeruginosa</italic>, <italic>n</italic>
</td><td>1</td><td>0</td></tr><tr valign="top"><td>
<italic>Streptococcus pneumoniae</italic>, <italic>n</italic>
</td><td>0</td><td>2</td></tr><tr valign="top"><td>
<italic>Haemophilus influenzae</italic>, <italic>n</italic>
</td><td>1</td><td>1</td></tr></tbody></table></table-wrap></p><p>The median PCT concentration was 0.113&#x000a0;&#x003bc;g/L (IQR, 0.054 to 0.270&#x000a0;&#x003bc;g/L), and 74 patients (41.1%) had PCT levels &#x0003c;0.1&#x000a0;&#x003bc;g/L, 30 (16.7%) had PCT levels between 0.1 and 0.25&#x000a0;&#x003bc;g/L and 76 (42.2%) had PCT levels &#x0003e;0.25&#x000a0;&#x003bc;g/L. PCT levels did not differ significantly between patients with sputum samples (0.106&#x000a0;&#x003bc;g/L; IQR, 0.050 to 0.266&#x000a0;&#x003bc;g/L) and those without (0.141&#x000a0;&#x003bc;g/L; IQR, 0.064 to 0.272&#x000a0;&#x003bc;g/L) (<italic>P</italic>&#x02009;=&#x02009;0.145).</p></sec><sec id="Sec9"><title>Primary outcome</title><p>In the PCT group, 38 patients received antibiotics according to the PCT algorithm. Overruling was observed in six patients with PCT &#x0003c;0.25&#x000a0;&#x003bc;g/L. The reasons for overruling included receiving mechanical ventilation (<italic>n</italic>&#x02009;=&#x02009;3), patient&#x02019;s request (<italic>n</italic>&#x02009;=&#x02009;1) and purulent sputum (<italic>n</italic>&#x02009;=&#x02009;2). Four patients in the PCT group from whom antibiotics were initially withheld (those with a PCT level &#x0003c;0.25&#x000a0;&#x003bc;g/L) received an antibiotic based on a PCT level &#x0003e;0.25&#x000a0;&#x003bc;g/L at the second measurement during reevaluation after 6 to 24&#x000a0;hours. Overall, antibiotic exposure was lower in patients for whom antibiotics were prescribed according to the algorithm based on PCT levels compared to standard therapy (48.9% vs. 87.8%, respectively; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) (RR, 0.56; 95% CI, 0.44 to 0.70; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). Thus, in spite of overruling, the PCT algorithm permitted a 44.3% reduction in antibiotic use.</p></sec><sec id="Sec10"><title>Secondary outcome</title><p>The rate of clinical success was comparable between the two groups. Fourteen patients (15.5%) in the PCT group and eleven (12.2%) in the control group received mechanical ventilation treatment (<italic>P</italic>&#x02009;=&#x02009;0.518). The median of antibiotic duration in the PCT group (6&#x000a0;days; IQR, 4 to 9&#x000a0;days) was similar to that in the control group (6&#x000a0;days; IQR, 3 to 8&#x000a0;days) (<italic>P</italic>&#x02009;=&#x02009;0.198). There were no significant differences between groups in laboratory measures, length of hospital stay or spirometry at discharge (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Patient characteristics and outcomes at discharge</bold>
<sup><bold>a</bold></sup>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>PCT group (</bold>
<bold><italic>n</italic></bold>&#x02009;
<bold>=&#x02009;90)</bold>
</th><th>
<bold>Control group (</bold>
<bold><italic>n</italic></bold>&#x02009;
<bold>=&#x02009;90)</bold>
</th><th>
<bold><italic>P</italic></bold>-<bold>value</bold>
</th></tr></thead><tbody><tr valign="top"><td>Antibiotic use, <italic>n</italic> (%)</td><td>44 (48.9)</td><td>79 (87.8)</td><td>&#x0003c;0.001</td></tr><tr valign="top"><td>Clinical success, <italic>n</italic> (%)</td><td>90 (100)</td><td>90 (100)</td><td>1.00</td></tr><tr valign="top"><td>Duration of antibiotic, days</td><td>6 (4 to 9)</td><td>6 (3 to 8)</td><td>0.198</td></tr><tr valign="top"><td>Length of hospital stay, days</td><td>9 (6 to 11)</td><td>8 (6 to 12)</td><td>0.380</td></tr><tr valign="top"><td>Need for intubation, <italic>n</italic> (%)</td><td>14 (15.5)</td><td>11 (12.2)</td><td>0.518</td></tr><tr valign="top"><td>FEV<sub>1</sub>,% of predicted value</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Prebronchodilator</td><td>70.9&#x02009;&#x000b1;&#x02009;12.8</td><td>72.4&#x02009;&#x000b1;&#x02009;11.2</td><td>0.404</td></tr><tr valign="top"><td>&#x02003;Postbronchodilator</td><td>75.4&#x02009;&#x000b1;&#x02009;11.6</td><td>77.1&#x02009;&#x000b1;&#x02009;12.5</td><td>0.345</td></tr><tr valign="top"><td>CRP, mg/L</td><td>9.3&#x02009;&#x000b1;&#x02009;3.4</td><td>9.7&#x02009;&#x000b1;&#x02009;4.2</td><td>0.509</td></tr><tr valign="top"><td>WBC, &#x000d7;10<sup>9</sup>/L</td><td>7.1&#x02009;&#x000b1;&#x02009;2.1</td><td>7.4&#x02009;&#x000b1;&#x02009;1.9</td><td>0.469</td></tr><tr valign="top"><td>PCT, &#x003bc;g/L</td><td>0.041 (0.028 to 0.063)</td><td>0.046 (0.032 to 0.071)</td><td>0.723</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>CRP, C-reactive protein; FEV<sub>1</sub>, Forced expiratory volume in 1&#x000a0;second; PCT, procalcitonin; WBC, white blood cells. Data are presented as number (%), median (IQR) or mean&#x02009;&#x000b1;&#x02009;SD.</p></table-wrap-foot></table-wrap></p><p>Clinical and laboratory measures of outcome, spirometry and ACT and AQLQ scores were similar at the 12-month follow-up visit in both groups (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). During the 12-month follow-up period, subsequent ED visits occurred in 119 cases (PCT group, 61 cases; control group, 58 cases; <italic>P</italic>&#x02009;=&#x02009;0.698), and systemic corticosteroids for &#x02265;3&#x000a0;days were needed in 89 cases (PCT group, 43 cases; control group, 46 cases; <italic>P</italic>&#x02009;=&#x02009;0.587). There were no significant differences in the exacerbation rate (78.8% in PCT group vs. 82.1% in control group, respectively; <italic>P</italic>&#x02009;=&#x02009;0.586) or in the hospitalization rate for exacerbations of asthma (8.2% in PCT group vs. 10.7% in control group, respectively; <italic>P</italic>&#x02009;=&#x02009;0.582) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The mean times to the first exacerbation and the first hospitalization due to exacerbation were also similar in both groups (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Comparison of patient characteristics and outcomes at the 12-month follow-up visit</bold>
<sup><bold>a</bold></sup>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>PCT group (</bold>
<bold><italic>n</italic></bold>&#x02009;
<bold>=&#x02009;85)</bold>
</th><th>
<bold>Control group (</bold>
<bold><italic>n</italic></bold>&#x02009;
<bold>=&#x02009;84)</bold>
</th><th>
<bold><italic>P-</italic></bold>
<bold>value</bold>
</th></tr></thead><tbody><tr valign="top"><td>Level of asthma control, <italic>n</italic> (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Fully controlled</td><td>13 (15.3)</td><td>10 (11.9)</td><td>0.520</td></tr><tr valign="top"><td>&#x02003;Controlled</td><td>48 (56.5)</td><td>51 (60.7)</td><td>0.575</td></tr><tr valign="top"><td>&#x02003;Partly controlled</td><td>18 (21.2)</td><td>15 (17.8)</td><td>0.586</td></tr><tr valign="top"><td>&#x02003;Uncontrolled</td><td>6 (7.1)</td><td>8 (9.5)</td><td>0.561</td></tr><tr valign="top"><td>FEV<sub>1</sub>,% of predicted value</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Prebronchodilator</td><td>76.7&#x02009;&#x000b1;&#x02009;11.8</td><td>77.9&#x02009;&#x000b1;&#x02009;12.4</td><td>0.520</td></tr><tr valign="top"><td>&#x02003;Postbronchodilator</td><td>83.5&#x02009;&#x000b1;&#x02009;13.4</td><td>84.7&#x02009;&#x000b1;&#x02009;12.7</td><td>0.551</td></tr><tr valign="top"><td>ACT score, mean (SD)</td><td>21.1&#x02009;&#x000b1;&#x02009;3.3</td><td>20.6&#x02009;&#x000b1;&#x02009;3.5</td><td>0.324</td></tr><tr valign="top"><td>AQLQ score, mean (SD)</td><td>5.04&#x02009;&#x000b1;&#x02009;1.17</td><td>5.07&#x02009;&#x000b1;&#x02009;1.21</td><td>0.788</td></tr><tr valign="top"><td>Clinical events during 12-month follow-up period</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Asthma exacerbations, <italic>n</italic> (%)</td><td>67 (78.8)</td><td>69 (82.1)</td><td>0.586</td></tr><tr valign="top"><td>&#x02003;&#x02003;&#x02003;Per patient per year</td><td>1.54&#x02009;&#x000b1;&#x02009;1.17</td><td>1.52&#x02009;&#x000b1;&#x02009;1.22</td><td>0.925</td></tr><tr valign="top"><td>&#x02003;Emergency room visits, <italic>n</italic> (%)</td><td>61 (71.8)</td><td>58 (69.0)</td><td>0.698</td></tr><tr valign="top"><td>&#x02003;&#x02003;&#x02003;Per patient per year</td><td>1.01&#x02009;&#x000b1;&#x02009;0.81</td><td>0.96&#x02009;&#x000b1;&#x02009;0.83</td><td>0.707</td></tr><tr valign="top"><td>&#x02003;Hospitalizations, <italic>n</italic> (%)</td><td>7 (8.2)</td><td>9 (10.7)</td><td>0.582</td></tr><tr valign="top"><td>&#x02003;Need for systemic corticosteroids for &#x02265;3&#x000a0;days, <italic>n</italic> (%)</td><td>43 (50.6)</td><td>46 (54.8)</td><td>0.587</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; FEV<sub>1</sub>, Forced expiratory volume in 1&#x000a0;second; PCT, Procalcitonin; Data are presented as number (%) or mean&#x02009;&#x000b1;&#x02009;SD.</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Kaplan-Meier estimates of time to first asthma exacerbation (A) and hospitalization (B) after hospital discharge.</bold> PCT, Procalcitonin.</p></caption><graphic xlink:href="13054_2014_471_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p>We observed a significant reduction in antibiotic use in patients hospitalized with severe acute exacerbations of asthma for whom a decision could be made on the basis of an algorithm of PCT measurements. Importantly, withholding antibiotic treatment did not cause apparent harm according to clinical and laboratory outcomes at discharge and during the 12-month follow-up period.</p><p>Exacerbation of asthma is often precipitated by a viral respiratory infection, and atypical bacteria such as <italic>Mycoplasma pneumoniae</italic> and <italic>Chlamydophila pneumoniae</italic> may play a role in its pathogenesis [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. Antibiotic use during treatment of asthma exacerbation remains controversial, and few patients are estimated to benefit from this type of antibiotic treatment. In the TELICAST study [<xref ref-type="bibr" rid="CR26">26</xref>], a total of 278 adults with acute exacerbation of asthma were randomly assigned to receive 10&#x000a0;days of treatment with oral telithromycin or placebo in addition to usual care. Patients in the telithromycin group had a significantly greater improvement in asthma symptoms, but they did not show an improvement in peak expiratory flow rates measured in the morning at home. However, routine use of antibiotics for exacerbations of asthma is of no benefit and may cause unwanted effects, so the empirical use of antibiotics is not recommended. In a randomized double-blind study [<xref ref-type="bibr" rid="CR27">27</xref>], Graham and colleagues assessed the value of amoxicillin in 60 adults admitted to the hospital with acute exacerbations of asthma, with 37 exacerbations treated with amoxicillin and 34 with placebo. Response to treatment was closely monitored, but no significant differences between groups were demonstrated with regard to improvement measured by length of hospital stay, time until 50% improvement in symptoms, patient self-assessment and respiratory function, and symptoms and respiratory function at discharge. More recently, in the AZISAST study [<xref ref-type="bibr" rid="CR28">28</xref>], 55 patients were randomly assigned to receive azithromycin and 54 were to receive placebo. Add-on treatment with azithromycin did not decrease the frequency of severe exacerbations of asthma and LRTI requiring antibiotics.</p><p>Under realistic clinical practice conditions, the challenge for physicians is to identify asthma patients with bacterial RTI for whom antimicrobial treatment is likely to be beneficial. Patients are often prescribed antibiotics despite clinical practice guideline recommendations against the empiric use of antibiotics in acute exacerbations of asthma [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Clinical signs and symptoms of acute asthma and bacterial RTI overlap, as do commonly used laboratory parameters such as C-reactive protein (CRP) and white blood cell (WBC) count, making it difficult for physicians to distinguish viral from bacterial infections in asthma patients [<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref>]. Patients with severe exacerbations are more often treated with antibiotics because of high morbidity and mortality. The routine use of standard laboratory tests such as CRP level and WBC count seems to be motivated more by their low cost, easy availability and historic practice rather than by their diagnostic accuracy. Moreover, the reliability of CRP level and/or WBC count for guiding antimicrobial therapy is limited by their late peak levels as well as their suboptimal specificity, especially in patients with systemic inflammation [<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>Circulating levels of PCT are elevated in patients with systemic bacterial infections, but they remain relatively low in patients with viral infections or inflammatory diseases [<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref>]. Hence, PCT levels may be used to support clinical decision-making for the initiation and discontinuation of antibiotic therapy [<xref ref-type="bibr" rid="CR35">35</xref>]. Since the first pilot study published in 2004 [<xref ref-type="bibr" rid="CR10">10</xref>], PCT-guided strategies for antibiotic treatment decision have gained much attention. Overall, it has been shown that PCT might be feasible in guiding antibiotic treatment in patients with acute exacerbations of COPD [<xref ref-type="bibr" rid="CR12">12</xref>] as well as in limiting treatment duration in patients with CAP [<xref ref-type="bibr" rid="CR11">11</xref>] and severe infectious diseases in the intensive care unit [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. The main effect has been achieved either by discouraging antibiotic initiation or by shortening the duration of antibiotic treatment without increased rates of adverse outcomes [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR37">37</xref>]. The use of PCT also has prognostic implications, as falling values correlate with good outcomes and static or increasing values correlate with adverse outcomes, including mortality [<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref>]. More recently, a PCT strategy was evaluated in primary care in patients with symptoms of acute respiratory infections, with results supporting the potential for substantial reductions in antibiotic use in this patient population [<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>Only a few asthma patients were included in two previous trials of PCT-guided therapy, [<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR13">13</xref>]. In our own previous study, only 34 patients with severe exacerbation asthma were included [<xref ref-type="bibr" rid="CR5">5</xref>]. The presently reported trial is, to our knowledge, the first clinical study focused on evaluation of the PCT test in its effectiveness in guiding antibiotic treatment of severe acute exacerbations of asthma.</p><p>However, some limitations of the present study should be recognized. First, we excluded patients older than 65&#x000a0;years of age, which may limit the application of our findings to older patients. Second, we did not conduct a formal cost&#x02013;benefit study. To evaluate if a PCT-based strategy is cost-efficient under real-life conditions, cost aspects should be carefully considered. Third, this study was performed in a single center with a high baseline use of antibiotics for the treatment of asthma. Reductions in antibiotic use by means of PCT therapy guidance will be less in centers that already use antibiotics for asthma less often. Fourth, because of its relatively small sample size, our study has limited power to prove the safety of the PCT strategy, and we cannot exclude a potential harm of reducing antibiotic therapy on the basis of PCT guidance. Taking into account the limited population size in the study, a multicenter trial that includes a large number of patients with severe exacerbation of asthma is desirable to validate our data. We emphasize that any infection is too complex to be reduced to a single cutoff of a surrogate marker, and biomarkers should complement rather than replace good clinical practice. Certainly, results from the use of biomarkers should be considered in light of the pretest probability of disease presence.</p></sec><sec id="Sec12" sec-type="conclusion"><title>Conclusions</title><p>The results of our study support the concept that PCT guidance reduces antibiotic exposure in patients with severe acute exacerbation of asthma without apparent harm. Given the prevalence of asthma and the duration of illness, a reduction in antibiotic prescriptions for the treatment of exacerbations could result in fewer side effects, lower costs and, in the long term, lead to diminishing drug resistance, particularly in countries such as China, where patients are suffering from the overuse of antibiotics [<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref>].</p></sec><sec id="Sec13"><title>Key messages</title><p><list list-type="bullet"><list-item><p>Antibiotic overuse in China is normal, and patients with severe acute exacerbations of asthma often receive inappropriate antibiotic treatment.</p></list-item><list-item><p>The results of this single-center study show that a significant reduction in antibiotic use in patients hospitalized with severe acute exacerbations of asthma for whom a decision could be made on the basis of an algorithm of PCT measurements.</p></list-item><list-item><p>Withholding antibiotic treatment on the basis of PCT guidance did not cause apparent harm for up to 12&#x000a0;months.</p></list-item><list-item><p>Additional larger multicenter studies are needed to confirm the usefulness of PCT guidance during treatment of severe asthma exacerbation.</p></list-item></list></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>ACT</term><def><p>Asthma Control Test</p></def></def-item><def-item><term>AQLQ</term><def><p>Asthma Quality of Life Questionnaire</p></def></def-item><def-item><term>CAP</term><def><p>Community-acquired pneumonia</p></def></def-item><def-item><term>CI</term><def><p>Confidence interval</p></def></def-item><def-item><term>COPD</term><def><p>Chronic obstructive pulmonary disease</p></def></def-item><def-item><term>CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term>ED</term><def><p>Emergency Department</p></def></def-item><def-item><term>ICS</term><def><p>Inhaled corticosteroid</p></def></def-item><def-item><term>IQR</term><def><p>Interquartile range</p></def></def-item><def-item><term>LABA</term><def><p>Long-acting &#x003b2;<sub>2</sub>-agonist</p></def></def-item><def-item><term>PCT</term><def><p>Procalcitonin</p></def></def-item><def-item><term>RR</term><def><p>Relative risk</p></def></def-item><def-item><term>RTI</term><def><p>Respiratory tract infection</p></def></def-item><def-item><term>SD</term><def><p>Standard deviation</p></def></def-item><def-item><term>WBC</term><def><p>White blood cell</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>WL, GZH and JGT had the idea for and initiated the study. LJL, GL, YZ and YCZ organized the data collection. WL and XMZ performed the statistical analyses and developed the initial draft of the manuscript. All authors amended and commented on the manuscript, revising it critically for important intellectual content. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was sponsored by a grant from the Shanghai Fifth People&#x02019;s Hospital Science Foundation (09YRCPY11, 2009; to WL) and Minhang District Natural Science Foundation of Shanghai (10MHWSJ11, 2010; to JGT). The founding bodies had no involvement in the design, collection, analysis or interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. The authors thank the medical and nursing staff of the Emergency Department at the Shanghai Fifth People&#x02019;s Hospital for their participation in the study.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masoli</surname><given-names>M</given-names></name><name><surname>Fabian</surname><given-names>D</given-names></name><name><surname>Holt</surname><given-names>S</given-names></name><name><surname>Beasley</surname><given-names>R</given-names></name><collab>Global Initiative for Asthma (GINA) Program</collab></person-group><article-title>The global burden of asthma: executive summary of the GINA Dissemination Committee report</article-title><source>Allergy</source><year>2004</year><volume>59</volume><fpage>469</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2004.00526.x</pub-id><pub-id pub-id-type="pmid">15080825</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannino</surname><given-names>DM</given-names></name><name><surname>Homa</surname><given-names>DM</given-names></name><name><surname>Akinbami</surname><given-names>LJ</given-names></name><name><surname>Moorman</surname><given-names>JE</given-names></name><name><surname>Gwynn</surname><given-names>C</given-names></name><name><surname>Redd</surname><given-names>SC</given-names></name></person-group><article-title>Surveillance for asthma&#x02013;United States, 1980&#x02013;1999</article-title><source>MMWR Surveill Summ</source><year>2002</year><volume>51</volume><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>SJ</given-names></name><name><surname>Wenzel</surname><given-names>SE</given-names></name></person-group><article-title>Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes</article-title><source>Ann Intern Med</source><year>2010</year><volume>152</volume><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-152-4-201002160-00008</pub-id><pub-id pub-id-type="pmid">20157138</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Global Initiative for Asthma (GINA): <bold>Global Strategy for Asthma Management and Prevention: Updated 2012.</bold> [http://www.ginasthma.org/documents/5/documents_variants/37 or <ext-link ext-link-type="uri" xlink:href="http://www.ginasthma.org/local/uploads/files/GINA_Report_March13_1.pdf">http://www.ginasthma.org/local/uploads/files/GINA_Report_March13_1.pdf</ext-link>] (accessed 10 August 2014).</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name></person-group><article-title>Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial</article-title><source>BMC Infect Dis</source><year>2013</year><volume>13</volume><fpage>596</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-13-596</pub-id><pub-id pub-id-type="pmid">24341820</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bafadhel</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>TW</given-names></name><name><surname>Reid</surname><given-names>C</given-names></name><name><surname>Medina</surname><given-names>MJ</given-names></name><name><surname>Batham</surname><given-names>S</given-names></name><name><surname>Barer</surname><given-names>MR</given-names></name><name><surname>Nicholson</surname><given-names>KG</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name></person-group><article-title>Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD</article-title><source>Chest</source><year>2011</year><volume>139</volume><fpage>1410</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1378/chest.10-1747</pub-id><pub-id pub-id-type="pmid">21030489</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderweil</surname><given-names>SG</given-names></name><name><surname>Tsai</surname><given-names>CL</given-names></name><name><surname>Pelletier</surname><given-names>AJ</given-names></name><name><surname>Espinola</surname><given-names>JA</given-names></name><name><surname>Sullivan</surname><given-names>AF</given-names></name><name><surname>Blumenthal</surname><given-names>D</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group><article-title>Inappropriate use of antibiotics for acute asthma in United States emergency departments</article-title><source>Acad Emerg Med</source><year>2008</year><volume>15</volume><fpage>736</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1111/j.1553-2712.2008.00167.x</pub-id><pub-id pub-id-type="pmid">18627585</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macfarlane</surname><given-names>JT</given-names></name><name><surname>Colville</surname><given-names>A</given-names></name><name><surname>Guion</surname><given-names>A</given-names></name><name><surname>Macfarlane</surname><given-names>RM</given-names></name><name><surname>Rose</surname><given-names>DH</given-names></name></person-group><article-title>Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community</article-title><source>Lancet</source><year>1993</year><volume>341</volume><fpage>511</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)90275-L</pub-id><pub-id pub-id-type="pmid">8094769</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>RP</given-names></name><name><surname>Wong</surname><given-names>MT</given-names></name></person-group><article-title>Managing antibiotic use&#x02013;impact of infection control</article-title><source>Clin Infect Dis</source><year>1999</year><volume>28</volume><fpage>1126</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1086/514753</pub-id><pub-id pub-id-type="pmid">10452646</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christ-Crain</surname><given-names>M</given-names></name><name><surname>Jaccard-Stolz</surname><given-names>D</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>Gencay</surname><given-names>MM</given-names></name><name><surname>Huber</surname><given-names>PR</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>B</given-names></name></person-group><article-title>Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>600</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)15591-8</pub-id><pub-id pub-id-type="pmid">14987884</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christ-Crain</surname><given-names>M</given-names></name><name><surname>Stolz</surname><given-names>D</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>C</given-names></name><name><surname>Miedinger</surname><given-names>D</given-names></name><name><surname>Huber</surname><given-names>PR</given-names></name><name><surname>Zimmerli</surname><given-names>W</given-names></name><name><surname>Harbarth</surname><given-names>S</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>B</given-names></name></person-group><article-title>Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>174</volume><fpage>84</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1164/rccm.200512-1922OC</pub-id><pub-id pub-id-type="pmid">16603606</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stolz</surname><given-names>D</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>Leuppi</surname><given-names>J</given-names></name><name><surname>Miedinger</surname><given-names>D</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>C</given-names></name><name><surname>Huber</surname><given-names>P</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>B</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name></person-group><article-title>Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy</article-title><source>Chest</source><year>2007</year><volume>131</volume><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1378/chest.06-1500</pub-id><pub-id pub-id-type="pmid">17218551</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briel</surname><given-names>M</given-names></name><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Mueller</surname><given-names>B</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Schild</surname><given-names>U</given-names></name><name><surname>Nusbaumer</surname><given-names>C</given-names></name><name><surname>P&#x000e9;riat</surname><given-names>P</given-names></name><name><surname>Bucher</surname><given-names>HC</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name></person-group><article-title>Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care</article-title><source>Arch Intern Med</source><year>2008</year><volume>168</volume><fpage>2000</fpage><lpage>2007</lpage><pub-id pub-id-type="doi">10.1001/archinte.168.18.2000</pub-id><pub-id pub-id-type="pmid">18852401</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name><name><surname>Thomann</surname><given-names>R</given-names></name><name><surname>Falconnier</surname><given-names>C</given-names></name><name><surname>Wolbers</surname><given-names>M</given-names></name><name><surname>Widmer</surname><given-names>I</given-names></name><name><surname>Neidert</surname><given-names>S</given-names></name><name><surname>Fricker</surname><given-names>T</given-names></name><name><surname>Blum</surname><given-names>C</given-names></name><name><surname>Schild</surname><given-names>U</given-names></name><name><surname>Regez</surname><given-names>K</given-names></name><name><surname>Schoenenberger</surname><given-names>R</given-names></name><name><surname>Henzen</surname><given-names>C</given-names></name><name><surname>Bregenzer</surname><given-names>T</given-names></name><name><surname>Hoess</surname><given-names>C</given-names></name><name><surname>Krause</surname><given-names>M</given-names></name><name><surname>Bucher</surname><given-names>HC</given-names></name><name><surname>Zimmerli</surname><given-names>W</given-names></name><name><surname>Mueller</surname><given-names>B</given-names></name><collab>ProHOSP Study Group</collab></person-group><article-title>Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1059</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1297</pub-id><pub-id pub-id-type="pmid">19738090</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkhardt</surname><given-names>O</given-names></name><name><surname>Ewig</surname><given-names>S</given-names></name><name><surname>Haagen</surname><given-names>U</given-names></name><name><surname>Giersdorf</surname><given-names>S</given-names></name><name><surname>Hartmann</surname><given-names>O</given-names></name><name><surname>Wegscheider</surname><given-names>K</given-names></name><name><surname>Hummers-Pradier</surname><given-names>E</given-names></name><name><surname>Welte</surname><given-names>T</given-names></name></person-group><article-title>Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection</article-title><source>Eur Respir J</source><year>2010</year><volume>36</volume><fpage>601</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1183/09031936.00163309</pub-id><pub-id pub-id-type="pmid">20185423</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>W</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name></person-group><article-title>Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia</article-title><source>Respirology</source><year>2011</year><volume>16</volume><fpage>819</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.2011.01978.x</pub-id><pub-id pub-id-type="pmid">21507143</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albrich</surname><given-names>WC</given-names></name><name><surname>Dusemund</surname><given-names>F</given-names></name><name><surname>Bucher</surname><given-names>B</given-names></name><name><surname>Meyer</surname><given-names>S</given-names></name><name><surname>Thomann</surname><given-names>R</given-names></name><name><surname>K&#x000fc;hn</surname><given-names>F</given-names></name><name><surname>Bassetti</surname><given-names>S</given-names></name><name><surname>Sprenger</surname><given-names>M</given-names></name><name><surname>Bachli</surname><given-names>E</given-names></name><name><surname>Sigrist</surname><given-names>T</given-names></name><name><surname>Schwietert</surname><given-names>M</given-names></name><name><surname>Amin</surname><given-names>D</given-names></name><name><surname>Hausfater</surname><given-names>P</given-names></name><name><surname>Carre</surname><given-names>E</given-names></name><name><surname>Gaillat</surname><given-names>J</given-names></name><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Regez</surname><given-names>K</given-names></name><name><surname>Bossart</surname><given-names>R</given-names></name><name><surname>Schild</surname><given-names>U</given-names></name><name><surname>Mueller</surname><given-names>B</given-names></name><collab>ProREAL Study Team</collab></person-group><article-title>Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in &#x0201c;real life&#x0201d;: an international, multicenter poststudy survey (ProREAL)</article-title><source>Arch Intern Med</source><year>2012</year><volume>172</volume><fpage>715</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1001/archinternmed.2012.770</pub-id><pub-id pub-id-type="pmid">22782201</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddel</surname><given-names>HK</given-names></name><name><surname>Taylor</surname><given-names>DR</given-names></name><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Boulet</surname><given-names>LP</given-names></name><name><surname>Boushey</surname><given-names>HA</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Casale</surname><given-names>TB</given-names></name><name><surname>Chanez</surname><given-names>P</given-names></name><name><surname>Enright</surname><given-names>PL</given-names></name><name><surname>Gibson</surname><given-names>PG</given-names></name><name><surname>de Jongste</surname><given-names>JC</given-names></name><name><surname>Kerstjens</surname><given-names>HA</given-names></name><name><surname>Lazarus</surname><given-names>SC</given-names></name><name><surname>Levy</surname><given-names>ML</given-names></name><name><surname>O&#x02019;Byrne</surname><given-names>PM</given-names></name><name><surname>Partridge</surname><given-names>MR</given-names></name><name><surname>Pavord</surname><given-names>ID</given-names></name><name><surname>Sears</surname><given-names>MR</given-names></name><name><surname>Sterk</surname><given-names>PJ</given-names></name><name><surname>Stoloff</surname><given-names>SW</given-names></name><name><surname>Sullivan</surname><given-names>SD</given-names></name><name><surname>Szefler</surname><given-names>SJ</given-names></name><name><surname>Thomas</surname><given-names>MD</given-names></name><name><surname>Wenzel</surname><given-names>SE</given-names></name><collab>American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations</collab></person-group><article-title>An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>180</volume><fpage>59</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1164/rccm.200801-060ST</pub-id><pub-id pub-id-type="pmid">19535666</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>RA</given-names></name><name><surname>Sorkness</surname><given-names>CA</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Schatz</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>JT</given-names></name><name><surname>Marcus</surname><given-names>P</given-names></name><name><surname>Murray</surname><given-names>JJ</given-names></name><name><surname>Pendergraft</surname><given-names>TB</given-names></name></person-group><article-title>Development of the asthma control test: a survey for assessing asthma control</article-title><source>J Allergy Clin Immunol</source><year>2004</year><volume>113</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2003.09.008</pub-id><pub-id pub-id-type="pmid">14713908</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juniper</surname><given-names>EF</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Epstein</surname><given-names>RS</given-names></name><name><surname>Ferrie</surname><given-names>PJ</given-names></name><name><surname>Jaeschke</surname><given-names>R</given-names></name><name><surname>Hiller</surname><given-names>TK</given-names></name></person-group><article-title>Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials</article-title><source>Thorax</source><year>1992</year><volume>47</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1136/thx.47.2.76</pub-id><pub-id pub-id-type="pmid">1549827</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan-Yeung</surname><given-names>M</given-names></name><name><surname>Law</surname><given-names>B</given-names></name><name><surname>Sheung</surname><given-names>SY</given-names></name><name><surname>Lam</surname><given-names>CL</given-names></name></person-group><article-title>Internal consistency, reproducibility, responsiveness, and construct validity of the Chinese (HK) version of the Asthma Quality of Life Questionnaire</article-title><source>Qual Life Res</source><year>2001</year><volume>10</volume><fpage>723</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1023/A:1013819108662</pub-id><pub-id pub-id-type="pmid">11871593</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>FM</given-names></name><name><surname>Lin</surname><given-names>JT</given-names></name><name><surname>Yin</surname><given-names>KS</given-names></name></person-group><article-title>Validity of asthma control test for asthma control assessment in Chinese primary care settings</article-title><source>Chest</source><year>2009</year><volume>135</volume><fpage>904</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1378/chest.08-0967</pub-id><pub-id pub-id-type="pmid">19118275</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>KG</given-names></name><name><surname>Kent</surname><given-names>J</given-names></name><name><surname>Ireland</surname><given-names>DC</given-names></name></person-group><article-title>Respiratory viruses and exacerbations of asthma in adults</article-title><source>BMJ</source><year>1993</year><volume>307</volume><fpage>982</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1136/bmj.307.6910.982</pub-id><pub-id pub-id-type="pmid">8241910</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>D</given-names></name><name><surname>Lieberman</surname><given-names>D</given-names></name><name><surname>Printz</surname><given-names>S</given-names></name><name><surname>Ben-Yaakov</surname><given-names>M</given-names></name><name><surname>Lazarovich</surname><given-names>Z</given-names></name><name><surname>Ohana</surname><given-names>B</given-names></name><name><surname>Friedman</surname><given-names>MG</given-names></name><name><surname>Dvoskin</surname><given-names>B</given-names></name><name><surname>Leinonen</surname><given-names>M</given-names></name><name><surname>Boldur</surname><given-names>I</given-names></name></person-group><article-title>Atypical pathogen infection in adults with acute exacerbation of bronchial asthma</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>167</volume><fpage>406</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1164/rccm.200209-996OC</pub-id><pub-id pub-id-type="pmid">12426232</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosentini</surname><given-names>R</given-names></name><name><surname>Tarsia</surname><given-names>P</given-names></name><name><surname>Canetta</surname><given-names>C</given-names></name><name><surname>Graziadei</surname><given-names>G</given-names></name><name><surname>Brambilla</surname><given-names>AM</given-names></name><name><surname>Aliberti</surname><given-names>S</given-names></name><name><surname>Pappalettera</surname><given-names>M</given-names></name><name><surname>Tantardini</surname><given-names>F</given-names></name><name><surname>Blasi</surname><given-names>F</given-names></name></person-group><article-title>Severe asthma exacerbation: role of acute <italic>Chlamydophila pneumoniae</italic> and <italic>Mycoplasma pneumoniae</italic> infection</article-title><source>Respir Res</source><year>2008</year><volume>9</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-9-48</pub-id><pub-id pub-id-type="pmid">18513407</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>SL</given-names></name><name><surname>Blasi</surname><given-names>F</given-names></name><name><surname>Black</surname><given-names>PN</given-names></name><name><surname>Martin</surname><given-names>RJ</given-names></name><name><surname>Farrell</surname><given-names>DJ</given-names></name><name><surname>Nieman</surname><given-names>RB</given-names></name><collab>TELICAST Investigators</collab></person-group><article-title>The effect of telithromycin in acute exacerbations of asthma</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>1589</fpage><lpage>1600</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa044080</pub-id><pub-id pub-id-type="pmid">16611950</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>VA</given-names></name><name><surname>Milton</surname><given-names>AF</given-names></name><name><surname>Knowles</surname><given-names>GK</given-names></name><name><surname>Davies</surname><given-names>RJ</given-names></name></person-group><article-title>Routine antibiotics in hospital management of acute asthma</article-title><source>Lancet</source><year>1982</year><volume>1</volume><fpage>418</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(82)91619-1</pub-id><pub-id pub-id-type="pmid">6121090</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusselle</surname><given-names>GG</given-names></name><name><surname>Vanderstichele</surname><given-names>C</given-names></name><name><surname>Jordens</surname><given-names>P</given-names></name><name><surname>Deman</surname><given-names>R</given-names></name><name><surname>Slabbynck</surname><given-names>H</given-names></name><name><surname>Ringoet</surname><given-names>V</given-names></name><name><surname>Verleden</surname><given-names>G</given-names></name><name><surname>Demedts</surname><given-names>IK</given-names></name><name><surname>Verhamme</surname><given-names>K</given-names></name><name><surname>Delporte</surname><given-names>A</given-names></name><name><surname>Demeyere</surname><given-names>B</given-names></name><name><surname>Claeys</surname><given-names>G</given-names></name><name><surname>Boelens</surname><given-names>J</given-names></name><name><surname>Padalko</surname><given-names>E</given-names></name><name><surname>Verschakelen</surname><given-names>J</given-names></name><name><surname>Van Maele</surname><given-names>G</given-names></name><name><surname>Deschepper</surname><given-names>E</given-names></name><name><surname>Joos</surname><given-names>GF</given-names></name></person-group><article-title>Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial</article-title><source>Thorax</source><year>2013</year><volume>68</volume><fpage>322</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2012-202698</pub-id><pub-id pub-id-type="pmid">23291349</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>B</given-names></name><name><surname>Harbarth</surname><given-names>S</given-names></name><name><surname>Stolz</surname><given-names>D</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>Mueller</surname><given-names>C</given-names></name><name><surname>Leuppi</surname><given-names>J</given-names></name><name><surname>Nusbaumer</surname><given-names>C</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name></person-group><article-title>Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia</article-title><source>BMC Infect Dis</source><year>2007</year><volume>7</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-7-10</pub-id><pub-id pub-id-type="pmid">17335562</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mas&#x000ed;a</surname><given-names>M</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>F</given-names></name><name><surname>Shum</surname><given-names>C</given-names></name><name><surname>Padilla</surname><given-names>S</given-names></name><name><surname>Navarro</surname><given-names>JC</given-names></name><name><surname>Flores</surname><given-names>E</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>I</given-names></name></person-group><article-title>Usefulness of procalcitonin levels in community-acquired pneumonia according to the Patients Outcome Research Team pneumonia severity index</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>2223</fpage><lpage>2229</lpage><pub-id pub-id-type="doi">10.1378/chest.128.4.2223</pub-id><pub-id pub-id-type="pmid">16236878</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Meer</surname><given-names>V</given-names></name><name><surname>Neven</surname><given-names>AK</given-names></name><name><surname>van den Broek</surname><given-names>PJ</given-names></name><name><surname>Assendelft</surname><given-names>WJ</given-names></name></person-group><article-title>Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review</article-title><source>BMJ</source><year>2005</year><volume>331</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1136/bmj.38483.478183.EB</pub-id><pub-id pub-id-type="pmid">15979984</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>L</given-names></name><name><surname>Gauvin</surname><given-names>F</given-names></name><name><surname>Amre</surname><given-names>DK</given-names></name><name><surname>Saint-Louis</surname><given-names>P</given-names></name><name><surname>Lacroix</surname><given-names>J</given-names></name></person-group><article-title>Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><fpage>206</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1086/421997</pub-id><pub-id pub-id-type="pmid">15307030</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>B</given-names></name><name><surname>Becker</surname><given-names>KL</given-names></name><name><surname>Sch&#x000e4;chinger</surname><given-names>H</given-names></name><name><surname>Rickenbacher</surname><given-names>PR</given-names></name><name><surname>Huber</surname><given-names>PR</given-names></name><name><surname>Zimmerli</surname><given-names>W</given-names></name><name><surname>Ritz</surname><given-names>R</given-names></name></person-group><article-title>Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>977</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1097/00003246-200004000-00011</pub-id><pub-id pub-id-type="pmid">10809269</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>B</given-names></name><name><surname>Becker</surname><given-names>KL</given-names></name></person-group><article-title>Procalcitonin: how a hormone became a marker and mediator of sepsis</article-title><source>Swiss Med Wkly</source><year>2001</year><volume>131</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">11820070</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Albrich</surname><given-names>W</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name><name><surname>Chastre</surname><given-names>J</given-names></name><name><surname>Mueller</surname><given-names>B</given-names></name></person-group><article-title>Procalcitonin for guidance of antibiotic therapy</article-title><source>Expert Rev Anti Infect Ther</source><year>2010</year><volume>8</volume><fpage>575</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1586/eri.10.25</pub-id><pub-id pub-id-type="pmid">20455686</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochreiter</surname><given-names>M</given-names></name><name><surname>K&#x000f6;hler</surname><given-names>T</given-names></name><name><surname>Schweiger</surname><given-names>AM</given-names></name><name><surname>Keck</surname><given-names>FS</given-names></name><name><surname>Bein</surname><given-names>B</given-names></name><name><surname>von Spiegel</surname><given-names>T</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name></person-group><article-title>Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>R83</fpage><pub-id pub-id-type="doi">10.1186/cc7903</pub-id><pub-id pub-id-type="pmid">19493352</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobre</surname><given-names>V</given-names></name><name><surname>Harbarth</surname><given-names>S</given-names></name><name><surname>Graf</surname><given-names>JD</given-names></name><name><surname>Rohner</surname><given-names>P</given-names></name><name><surname>Pugin</surname><given-names>J</given-names></name></person-group><article-title>Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>177</volume><fpage>498</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1164/rccm.200708-1238OC</pub-id><pub-id pub-id-type="pmid">18096708</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouadma</surname><given-names>L</given-names></name><name><surname>Luyt</surname><given-names>CE</given-names></name><name><surname>Tubach</surname><given-names>F</given-names></name><name><surname>Cracco</surname><given-names>C</given-names></name><name><surname>Alvarez</surname><given-names>A</given-names></name><name><surname>Schwebel</surname><given-names>C</given-names></name><name><surname>Schortgen</surname><given-names>F</given-names></name><name><surname>Lasocki</surname><given-names>S</given-names></name><name><surname>Veber</surname><given-names>B</given-names></name><name><surname>Dehoux</surname><given-names>M</given-names></name><name><surname>Bernard</surname><given-names>M</given-names></name><name><surname>Pasquet</surname><given-names>B</given-names></name><name><surname>R&#x000e9;gnier</surname><given-names>B</given-names></name><name><surname>Brun-Buisson</surname><given-names>C</given-names></name><name><surname>Chastre</surname><given-names>J</given-names></name><name><surname>Wolff</surname><given-names>M</given-names></name><collab>PRORATA trial group</collab></person-group><article-title>Use of procalcitonin to reduce patients&#x02019; exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>463</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61879-1</pub-id><pub-id pub-id-type="pmid">20097417</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hohn</surname><given-names>A</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Gehrt</surname><given-names>A</given-names></name><name><surname>Bernhardt</surname><given-names>K</given-names></name><name><surname>Bein</surname><given-names>B</given-names></name><name><surname>Wegscheider</surname><given-names>K</given-names></name><name><surname>Hochreiter</surname><given-names>M</given-names></name></person-group><article-title>Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock</article-title><source>BMC Infect Dis</source><year>2013</year><volume>13</volume><fpage>158</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-13-158</pub-id><pub-id pub-id-type="pmid">23547790</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>S</given-names></name><name><surname>Heikkinen</surname><given-names>M</given-names></name><name><surname>Pettil&#x000e4;</surname><given-names>V</given-names></name><name><surname>Alila</surname><given-names>S</given-names></name><name><surname>V&#x000e4;is&#x000e4;nen</surname><given-names>S</given-names></name><name><surname>Pulkki</surname><given-names>K</given-names></name><name><surname>Kolho</surname><given-names>E</given-names></name><name><surname>Ruokonen</surname><given-names>E</given-names></name><collab>Finnsepsis Study Group</collab></person-group><article-title>Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><fpage>R205</fpage><pub-id pub-id-type="doi">10.1186/cc9327</pub-id><pub-id pub-id-type="pmid">21078153</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Maurer</surname><given-names>P</given-names></name><name><surname>Punjabi</surname><given-names>V</given-names></name><name><surname>Desai</surname><given-names>A</given-names></name><name><surname>Amin</surname><given-names>DN</given-names></name><name><surname>Gluck</surname><given-names>E</given-names></name></person-group><article-title>Procalcitonin decrease over 72&#x000a0;hours in US critical care units predicts fatal outcome in sepsis patients</article-title><source>Crit Care</source><year>2013</year><volume>17</volume><fpage>R115</fpage><pub-id pub-id-type="doi">10.1186/cc12787</pub-id><pub-id pub-id-type="pmid">23787145</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>P</given-names></name><name><surname>Baquero</surname><given-names>F</given-names></name><name><surname>Cars</surname><given-names>O</given-names></name><name><surname>File</surname><given-names>T</given-names></name><name><surname>Garau</surname><given-names>J</given-names></name><name><surname>Klugman</surname><given-names>K</given-names></name><name><surname>Low</surname><given-names>DE</given-names></name><name><surname>Rubinstein</surname><given-names>E</given-names></name><name><surname>Wise</surname><given-names>R</given-names></name><collab>Consensus Group on Resistance and Prescribing in Respiratory Tract Infection</collab></person-group><article-title>Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence</article-title><source>J Antimicrob Chemother</source><year>2002</year><volume>49</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/jac/49.1.31</pub-id><pub-id pub-id-type="pmid">11751764</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>St&#x000e5;lsby Lundborg</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name></person-group><article-title>Knowledge, attitudes, and practices of parents in rural China on the use of antibiotics in children: a cross-sectional study</article-title><source>BMC Infect Dis</source><year>2014</year><volume>14</volume><fpage>112</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-14-112</pub-id><pub-id pub-id-type="pmid">24576064</pub-id></element-citation></ref></ref-list></back></article>